Macular edema causes the building-up of fluid in macula region of the eye. The macula is a light sensitive tissue, present at the center of the retina and is responsible for the sharp, straight headed vision. Building-up of fluid in macula region leads the vision to distort. Diabetic retinopathy (which is most common in diabetic patients) is observed as the common cause of macular edema. However, macular edema can also occur after surgery associated with age related macular degeneration or inflammatory disease of the eye. Blurred vision and vision loss are observed in most of the patients with macular edema. The Shahid Beheshti University of Medical Sciences is in the process of developing bevacizumab as an angiogenesis inhibitor for the treatment of macular edema. Bayer AG is in the process of developing aflibercept as a vascular endothelial growth factor-A inhibitor for the treatment of macular edema. Some companies having the pipeline of macular edema include Clearside Biomedical, Inc., Chengdu Kanghong Biotech Co., Ltd., Novartis AG, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.